Anti-b-catenin antibody (Full length) [ZM13] (STJ180299)

SKU:
STJ180299
€201.88 - €660.63
Free Shipping
Processing The item has been added

Host: Mouse
Applications: IHC-P
Reactivity: Human
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description : Mouse monoclonal antibody anti-b-catenin (Full length) is suitable for use in Immunohistochemistry research applications.
Clonality : Monoclonal
Clone ID : ZM13
Conjugation: Unconjugated
Isotype: IgG2b/Kappa
Formulation: Tris-HCI buffer containing stabilizing protein (BSA) and <0.1% ProClin
Purification: Affinity purified
Dilution Range: 1:100‐200
Storage Instruction: Store at 2‐8°C for up to 24 months. Predilute: Ready to use, no reconstitution necessary. Concentrate: Use dilution range and appropriate lab‐standardized diluent. Stability after dilution: 7 days at 24°C, 3 months at 2‐8°C, 6months at ‐20°C.
Immunogen Region: Full length
Specificity: Positive control: Fibromatosis or transitional cell carcinoma
Immunogen: Recombinant full-length human beta-catenin (CTNNB1) protein
Background Beta-catenin associates with the cytoplasmic portion of E-cadherin, which is necessary for the function of E-cadherin as an adhesion molecule. In normal tissues, beta-catenin is localized to the membrane of epithelial cells, consistent with its role in the cell adhesion complex. In breast ductal neoplasia, beta-catenin is usually localized in cellular membranes. However, in lobular neoplasia, a marked redistribution of beta-catenin throughout the cytoplasm results in a diffuse cytoplasmic pattern. Immuno-staining of beta-catenin and E-cadherin helps in the accurate identification of ductal and lobular neoplasms, including a distinction between low-grade ductal carcinoma in situ (DCIS) and lobular carcinoma. Additionally, some rectal and gastric adenocarcinomas demonstrate diffuse cytoplasmic beta-catenin staining and a lack of membranous staining, mimicking the staining pattern observed with lobular breast carcinomas.

Information sourced from Uniprot.org